Literature DB >> 9129209

Phenotypic and functional differences between human dendritic cells derived in vitro from hematopoietic progenitors and from monocytes/macrophages.

P L Triozzi1, W Aldrich.   

Abstract

We compared dendritic cells (DC) derived from CD34+ hematopoietic progenitor cells with tumor necrosis factor alpha and granulocyte-macrophage colony-stimulating factor (GM-CSF) to DC derived from monocytes/macrophages with interleukin-4 (IL-4) and GM-CSF. Monocyte/macrophage-derived DC demonstrated higher levels of CD1a, lower levels of CD14, greater stimulatory activity in mixed lymphocyte reactions, and greater capacity to present soluble protein antigen than CD34+ cell-derived DC. Lymphocytes stimulated with antigen-pulsed, monocyte/macrophage-derived DC produced more IL-10 than those stimulated with antigen-pulsed, CD34+-derived DC. Whereas CD1a+ DC could be derived from CD34+ cells in serum-free- and human-sera-containing cultures, the derivation of CD1a+ DC from monocytes/macrophages required the presence of fetal calf serum. The spectrum of cytokine mRNA expression, the presentation of peptide antigen, and the sensitivity to human immunodeficiency virus-1 infection of CD34(+)- and monocyte/macrophage-derived DC were comparable. Although cells derived by both methods are potent antigen-presenting cells, there are differences between DC derived in vitro from hematopoietic progenitors and from monocytes/macrophages that may influence their in vivo activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129209     DOI: 10.1002/jlb.61.5.600

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  9 in total

1.  Professional and non-professional antigen-presenting cells in the porcine small intestine.

Authors:  K Haverson; S Singha; C R Stokes; M Bailey
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

2.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

3.  Phenotype and polarization of autologous T cells by biomaterial-treated dendritic cells.

Authors:  Jaehyung Park; Michael H Gerber; Julia E Babensee
Journal:  J Biomed Mater Res A       Date:  2014-03-25       Impact factor: 4.396

Review 4.  Dendritic cells in the host response to implanted materials.

Authors:  Benjamin G Keselowsky; Jamal S Lewis
Journal:  Semin Immunol       Date:  2017-05-07       Impact factor: 11.130

Review 5.  Immune modulation by dendritic-cell-based cancer vaccines.

Authors:  Chaitanya Kumar; Sakshi Kohli; Poonamalle Parthasarathy Bapsy; Ashok Kumar Vaid; Minish Jain; Venkata Sathya Suresh Attili; Bandana Sharan
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826

6.  Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.

Authors:  R Chavan; K A Marfatia; I C An; D A Garber; M B Feinberg
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  Interactions of dendritic cells with fibronectin and endothelial cells.

Authors:  C Jancic; H E Chuluyan; A Morelli; A Larregina; E Kolkowski; M Saracco; M Barboza; W S Leiva; L Fainboim
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

8.  Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics.

Authors:  L Oehler; O Majdic; W F Pickl; J Stöckl; E Riedl; J Drach; K Rappersberger; K Geissler; W Knapp
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

9.  Dendritic cell appearance and differentiation during early and late stages of rat stomach carcinogenesis.

Authors:  Motoi Takeuchi; Masami Yamamoto; Masae Tatematsu; Kazumasa Miki; Yoshiyuki Sakaki; Chie Furihata
Journal:  Jpn J Cancer Res       Date:  2002-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.